HHHFNC与nCPAP治疗早产儿呼吸窘迫综合征多中心研究

    A multicenter study of HHHFNC and nCPAP in the treatment of premature infants with RDS

    • 摘要:
      目的探讨加温湿化高流量鼻导管通气(HHHFNC)与经鼻持续气道正压通气(nCPAP)治疗早产儿呼吸窘迫综合征(RDS)的临床效果。
      方法采用多中心前瞻性临床随机对照研究方法,将三家治疗中心诊断为RDS需要无创呼吸支持的早产儿260例纳入研究,根据体质量分为≤1 500 g组120例和>1 500 g组140例,再按照随机分组原则将每组分为HHHFNC组和nCPAP组。比较各组主要观察指标(治疗失败率、再插管率、医院内病死率、无创通气时间和用氧时间)和次要观察指标鼻损伤、腹胀、肺气漏、Ⅲ~Ⅳ级颅内出血(IVH)和败血症发生率。
      结果主要观察指标比较,体质量≤1 500 g组: HHHFNC组无创通气时间和用氧时间均明显高于nCPAP组(P < 0.01),2组治疗失败率、医院内病死率和再插管率差异均无统计学意义(P>0.05);体质量>1 500 g组: HHHFNC组与nCPAP组治疗失败率、无创通气时间、用氧时间、医院内病死率和再插管率差异均无统计学意义(P>0.05)。次要观察指标比较,体质量≤1 500 g组: HHHFNC组鼻损伤和腹胀发生率均明显低于nCPAP组(P < 0.01),2组肺气漏、Ⅲ~Ⅳ级IVH及败血症发生率差异均无统计学意义(P>0.05);体质量>1 500 g组: HHHFNC组鼻损伤发生率明显低于nCPAP组(P < 0.01),2组腹胀、肺气漏、Ⅲ~Ⅳ级IVH及败血症发生率差异均无统计学意义(P>0.05)。
      结论HHHFNC可作为体质量>1 500 g早产儿轻中度RDS的首选呼吸支持模式。

       

      Abstract:
      ObjectiveTo explore the clinical effect of heated humidified high flow nasal cannula (HHHFNC) and nasal continuous positive airway pressure (nCPAP) in the treatment of premature infants with respiratory distress syndrome (RDS).
      MethodsA multicenter, prospective, randomized controlled clinical study was carried out. Two hundred and sixty premature infants diagnosed with RDS requiring non-invasive respiratory support in three treatment centers were included in the study. According to the body mass, the infants were divided into the body mass ≤1 500 g group (n=120) and body mass >1 500 g group(n=140), then the two groups were randomly subdivided into the HHHFNC group and nCPAP group. The primary observation indexes (treatment failure rate, re-intubation rate, hospital mortality rate, non-invasive ventilation time and oxygen use time) and the secondary observation indexes the incidence of nasal injury, abdominal distension, pulmonary air leakage, grade Ⅲ-Ⅳ intra-ventricular hemorrhage (IVH) and sepsis were compared among the groups.
      ResultsAs for the primary observation indexes, in the body mass ≤1 500 g group, the non-invasive ventilation time and oxygen use time in the HHHFNC group were significantly higher than those in the nCPAP group (P < 0.01), and there were no significant differences in the treatment failure rate, hospital mortality rate and re-intubation rate between the two groups (P>0.05);in the body mass >1 500 g group, there were no significant differences in the treatment failure rate, non-invasive ventilation time, oxygen use time, hospital mortality rate and re-intubation rate between the HHHFNC group and nCPAP group (P>0.05). As for the secondary observation indexes, in the body mass ≤1 500 g group, the incidence of nasal injury and abdominal distension in the HHHFNC group were significantly lower than those in the nCPAP group (P < 0.01), and there were no significant differences in the incidence of pulmonary air leakage, grade Ⅲ-Ⅳ IVH and sepsis between the two groups (P>0.05);in the body mass >1 500 g group, the incidence of nasal injury in the HHHFNC group was significantly lower than that in the nCPAP group (P < 0.01), and there were no significant differences in the incidence of abdominal distension, pulmonary air leakage, grade Ⅲ-Ⅳ IVH and sepsis between the two groups (P>0.05).
      ConclusionsHHHFNC can be used as the preferred respiratory support mode for mild to moderate RDS in preterm infants with body mass >1 500 g.

       

    /

    返回文章
    返回